Prognostic Factors and Treatment Effect Modifier Candidates in Advanced HER2-Mutant NSCLC: A Targeted Literature Review

Background: The expanding availability of targeted therapies for HER2-mutant non-small-cell lung cancer (NSCLC) has led to increased interest in understanding the baseline characteristics of patients that may impact clinical outcomes. This literature review evaluates prognostic factors and treatment effect modifiers in HER2-mutant NSCLC to inform indirect treatment comparison (ITC). Methods: A targeted literature review (TLR) was conducted and reported in accordance with an adapted PRISMA framework. The review included observational studies and clinical trials assessing survival outcomes among adults with advanced HER2-mutant NSCLC, irrespective of prior systemic therapy. Subgroups of interest included age, sex, smoking status, Eastern Cooperative Oncology Group performance status (ECOG PS), metastatic status, prior treatment history, HER2-mutation subtype, and other clinically relevant baseline characteristics. Searches were conducted in Embase and MEDLINE to identify English-language publications from January 2019 to 20 December 2025. Results: Based on data from 33 included publications (19 observational studies and 14 publications reporting results from 11 clinical trials), most demographic factors, including age, sex, and smoking status, were not found to be of consistent prognostic or predictive value in HER2-mutant NSCLC patients. However, ECOG PS and metastatic burden showed the most consistent prognostic associations with clinical outcomes, whereas associations for HER2-mutation subtype (especially the YVMA/Y772_A775dup variant) were heterogeneous, appeared to differ by treatment and were largely exploratory. TP53 co-mutations were associated with poorer outcomes in all TKI-treated cohorts reporting them; no evidence is available for other treatment classes. Conclusions: These findings provide a structured evidence base for variable selection and sensitivity analyses in ITCs, while underscoring the need for prospective controlled studies capable of formally evaluating treatment heterogeneity in this molecularly distinct population.

Authors

Publication Details

Journal
Cancers
Published
2026-11-13
DOI
https://doi.org/10.3390/cancers18223640
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognostic Factors and Treatment Effect Modifier Candidates in Advanced HER2-Mutant NSCLC: A Targeted Literature Review

Anne-Mary Lewis-Mikhael, Vadim Bernard-Gauthier, Federico Manevy, Noman Paracha et al.
6 links
Cancers
Lung Cancer Treatments and Mutations
article

Prognostic Factors and Treatment Effect Modifier Candidates in Advanced HER2-Mutant NSCLC: A Targeted Literature Review

Anne-Mary Lewis-Mikhael, Vadim Bernard-Gauthier, Federico Manevy, Noman Paracha, Lucía Regales, Kostas Papadakis, Xuan Wang
article en

Abstract

Background: The expanding availability of targeted therapies for HER2-mutant non-small-cell lung cancer (NSCLC) has led to increased interest in understanding the baseline characteristics of patients that may impact clinical outcomes. This literature review evaluates prognostic factors and treatment effect modifiers in HER2-mutant NSCLC to inform indirect treatment comparison (ITC). Methods: A targeted literature review (TLR) was conducted and reported in accordance with an adapted PRISMA framework. The review included observational studies and clinical trials assessing survival outcomes among adults with advanced HER2-mutant NSCLC, irrespective of prior systemic therapy. Subgroups of interest included age, sex, smoking status, Eastern Cooperative Oncology Group performance status (ECOG PS), metastatic status, prior treatment history, HER2-mutation subtype, and other clinically relevant baseline characteristics. Searches were conducted in Embase and MEDLINE to identify English-language publications from January 2019 to 20 December 2025. Results: Based on data from 33 included publications (19 observational studies and 14 publications reporting results from 11 clinical trials), most demographic factors, including age, sex, and smoking status, were not found to be of consistent prognostic or predictive value in HER2-mutant NSCLC patients. However, ECOG PS and metastatic burden showed the most consistent prognostic associations with clinical outcomes, whereas associations for HER2-mutation subtype (especially the YVMA/Y772_A775dup variant) were heterogeneous, appeared to differ by treatment and were largely exploratory. TP53 co-mutations were associated with poorer outcomes in all TKI-treated cohorts reporting them; no evidence is available for other treatment classes. Conclusions: These findings provide a structured evidence base for variable selection and sensitivity analyses in ITCs, while underscoring the need for prospective controlled studies capable of formally evaluating treatment heterogeneity in this molecularly distinct population.

CancersVol. 18(22)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon